A recall of one specific generic three-in-one blood pressure pill is what pushed the search term olmesartan amlodipine hydrochlorothiazide recall into the news in early November 2026. Macleods Pharmaceuticals recalled certain bottles of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets in the 40 mg/10 mg/12.5 mg strength because they failed a dissolution specification. The recall is limited to two lots of the generic product; the brand-name version, Tribenzor, is not affected. Taiwan's FDA then stated on November 2, 2026 that the affected lots were never imported or sold there.
Olmesartan medoxomil, amlodipine and hydrochlorothiazide is a single tablet that combines three blood pressure medicines from three different drug classes. Olmesartan is an angiotensin II receptor blocker, amlodipine is a calcium channel blocker, and hydrochlorothiazide is a thiazide diuretic that helps the body excrete excess salt and water. Doctors prescribe this fixed-dose combination when one or two agents are not enough to control blood pressure, because a single tablet is easier to take than three separate ones. The recalled product is the generic equivalent of the brand Tribenzor.
The recall was carried out by Macleods Pharma USA, Inc. of Princeton, New Jersey, with the product manufactured by Macleods Pharmaceuticals Ltd in Daman, India. It covers 3,744 bottles of the 40 mg/10 mg/12.5 mg tablets, according to reporting from abc10.com. Of those, 3,528 bottles were 30-count packages and 216 were 90-count packages, based on figures published by The Epoch Times. The bottles were distributed across the United States between November 21, 2025 and April 27, 2026.
Only two lots are involved, and both carry an expiry date of May 31, 2027 according to the California Board of Pharmacy notice. The 30-count bottle has National Drug Code 33342-246-07 and lot number 12251163A, while the 90-count bottle has NDC 33342-246-10 and lot number 12251163B. The NDC is the numerical identifier printed on a US medicine label that tells you the labeler, product and package size. If your bottle shows a different lot number, it is not part of this recall.
The recall was triggered because the product failed dissolution specifications, which is a test of how quickly and completely a tablet releases its active ingredient in the body. In nine-month stability testing of batch 12251163B, the mean olmesartan medoxomil dissolution across 24 units came out at 79 percent, against a requirement of not less than 80 percent, according to the California Board of Pharmacy notice. Individual units still met the S3 criteria, and the assay, related substances and the amlodipine and hydrochlorothiazide dissolution results all passed. Stability testing means checking whether a medicine still meets its specification after a period of storage.
The manufacturer's health hazard assessment concluded that using the affected tablets could cause a temporary and medically reversible reduction in blood pressure control. In plain terms, the olmesartan in those tablets may be absorbed more slowly or less fully, so the drug may not work as well while a patient is taking that bottle. The assessment rated the probability of serious harm as remote, and no adverse events had been reported at the time of the recall notice. That assessment is the company's own estimate, not a measurement of what happened to individual patients.
The recall was initiated on October 7, 2026, and the FDA classified it as Class II on October 26, 2026, according to abc10.com. The FDA defines a Class II recall as one where use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This is a middle category: it is more serious than a Class III recall but less serious than a Class I, which covers products likely to cause serious harm or death. The FDA event number is 100113 and the recall number is D-0077-2027.
There is a gap between when a company begins pulling a product and when the FDA posts the classification, and that gap explains part of the confusion around this story. The Macleods recall was initiated on October 7, 2026, but the FDA did not publish its Class II classification until October 26, 2026, which is when many news outlets picked it up. The bottles themselves had already been distributed between late November 2025 and late April 2026, well before the recall began. Recalls commonly surface publicly only after the FDA finishes reviewing the company's submission.
Around the same period, Ascend Laboratories recalled 11,424 bottles of amlodipine and olmesartan 10 mg/40 mg tablets, lot 25120696, expiring December 31, 2026. That recall was also for a dissolution failure, and the product was made by Alkem Laboratories, according to The Epoch Times. It was initiated on October 6, 2026, and the FDA classified it as Class II on October 16, 2026. The two events are separate recalls of different products by different companies, but their proximity in time is part of why blood pressure medicine recalls drew wider coverage.
On November 2, 2026, Taiwan's FDA stated that the affected Macleods lots had neither been imported into nor sold in Taiwan, so the domestic supply was unaffected, according to the Central News Agency. The Taiwanese product name cited in that statement was 脈思歐膜衣錠 40/10/12.5 毫克, under permit number 卫部药输字第028932号. A regulator commenting on a foreign recall usually means it has checked its own import records and wants to reassure patients at home. This statement is what pushed the topic into Asian news feeds.
The search spike came from two news events landing within about a day of each other. US consumer coverage of the Macleods recall appeared on November 1 and 2, 2026, and Taiwan's FDA statement followed on November 2, 2026. When a regulator in one country confirms that a recall elsewhere does not touch its own market, the story travels into that country's media, and readers there begin searching the drug names. That combination of a US recall plus an Asian regulatory statement is what made a fairly small recall trend globally.
It is worth keeping the scale in perspective: just over 3,700 bottles is a small fraction of the total supply of this combination product. The recall is limited to two lot numbers with one expiry date, not to the product as a whole or to other strengths. Macleods has not issued a press release or consumer instructions, according to Yahoo News, so most information has come from regulator postings and press coverage. How many of those bottles remain in patients' hands is not publicly known.
To check, find the lot number and NDC on your prescription label or bottle and compare them with lot 12251163A (NDC 33342-246-07, 30-count) and lot 12251163B (NDC 33342-246-10, 90-count). If neither matches, your bottle is outside this recall. If your pharmacy label does not show a lot number, ask the pharmacist to check the dispensing record, since pharmacies track the lots they dispense. Your pharmacist can also confirm whether your tablets were made by Macleods at all.
If your bottle matches one of the recalled lots, do not stop taking the medication on your own. The FDA notes that people can generally continue medicines in a Class II recall but should check with their doctor or pharmacist first, according to Yahoo News. Ask your pharmacist about a replacement supply, and you or your pharmacist can contact Macleods or report the issue through the FDA's MedWatch program. Stopping blood pressure treatment abruptly can be riskier than continuing a tablet that may work slightly less well.
The expected problem is reduced absorption of one ingredient, not contamination, a wrong dose or a poisonous substance. That is why the guidance centers on replacing the bottle under professional advice rather than on an emergency. Blood pressure medicines work continuously, so an interruption matters more than a small drop in one component's absorption. Because the hazard assessment rated serious harm as remote, this is a supply-quality issue rather than an acute safety crisis.
Dissolution testing measures how much of the active ingredient dissolves out of a tablet under standardized laboratory conditions over time. Regulators set a limit, often written as Q, which is the percentage of the labeled amount that must dissolve; here the requirement was not less than 80 percent. A result of 79 percent is a marginal miss, not a collapse, which is consistent with the assessment that any effect on patients would be modest and reversible. The test is a quality check on the manufacturing process and on how the product holds up during storage.
Several things are not publicly explained: how many of the recalled bottles have already been used or remain with patients, and why the two lots failed dissolution in the first place. The California Board of Pharmacy notice does not state a root cause, and the company has not issued consumer-facing instructions. The FDA classification and the recall notice describe what is being recalled and why, but not the internal manufacturing investigation. Anyone wanting those details would need to follow later FDA enforcement reports or contact the manufacturer directly.
The core technical details come from a California Board of Pharmacy recall alert, which reproduces the dissolution figures, lot numbers, NDCs and the health hazard assessment. The FDA classification and dates are reported by abc10.com, while bottle counts and the Ascend Laboratories recall are reported by The Epoch Times. Taiwan's position is reported by the Central News Agency, and consumer guidance is summarized by Yahoo News. Because these are secondary reports of regulatory documents, patients should treat their own pharmacy as the authoritative source for their specific bottle.
Recalls of blood pressure medicines for dissolution or impurity problems have appeared repeatedly in recent years, and this case fits that pattern. What distinguishes a dissolution failure is that the tablet is not contaminated; it simply releases its ingredient outside the specified range. That is why regulators can classify such events as Class II and advise patients to keep taking the medicine while arranging a replacement. Reading recall news with that distinction in mind prevents unnecessary alarm over a quality-control miss.
The practical answer is short: check your lot number, and if it matches 12251163A or 12251163B, ask your pharmacist for a replacement rather than stopping treatment. If it does not match, no action is needed beyond normal medication management. Brand-name Tribenzor is not part of this recall, and Taiwan's market was confirmed unaffected. For anyone uncertain, the pharmacist, the prescribing doctor or the FDA's MedWatch program are the right places to get an answer about a specific bottle.
